At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 228 enrolled
Drug / intervention
Blood sampling for antibody determinationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study
In Brief
A Phase 3 clinical trial evaluating Blood sampling for antibody determination for Cervical Intraepithelial Neoplasia. Completed, enrolled 228 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study. No new subjects will be enrolled in this extension study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Intraepithelial Neoplasia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartFeb 2018
Primary CompletionJun 2018
TodayJul 2026
First PostedNov 28, 2017
Enrollment StartFeb 28, 2018
Primary CompletionJun 29, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.6 years ago
Interventions
Blood sampling for antibody determinationprocedure
In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.